Cargando…

Nonbrain metastases seen on magnetic resonance imaging during metastatic brain tumor screening

Although metastases found during head magnetic resonance imaging (MRI) are not limited to metastatic brain tumors, the MRI is a very common method for “brain metastasis screening,” a modality that is being increasingly performed. In this review, we describe MRI findings of nonbrain metastases and di...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Mio, Kashiwagi, Nobuo, Nakanishi, Katsuyuki, Maeda, Noboru, Nakaya, Yasuhiro, Tanaka, Junichiro, Watanabe, Shinichiro, Hongyo, Hidenari, Tanaka, Yu, Yamada, Sawaka, Kawata, Atsushi, Toda, Sou, Takano, Koji, Arita, Hideyuki, Tomiyama, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066091/
https://www.ncbi.nlm.nih.gov/pubmed/36374473
http://dx.doi.org/10.1007/s11604-022-01362-2
Descripción
Sumario:Although metastases found during head magnetic resonance imaging (MRI) are not limited to metastatic brain tumors, the MRI is a very common method for “brain metastasis screening,” a modality that is being increasingly performed. In this review, we describe MRI findings of nonbrain metastases and discuss ways to avoid missing these lesions. Metastatic cranial bone tumors are among the most common nonbrain metastatic lesions found on head MRI, followed by leptomeningeal carcinomatosis. The other less-frequent metastatic lesions include those in the ventricle/choroid plexus, the pituitary gland and stalk, and the pineal gland. Metastases in the head and neck area, as well as cranial and intracranial lesions, should be carefully evaluated. Furthermore, direct geographical invasion, perineural spread, and double cancers should also be considered. While it is important to recognize these metastatic lesions on MRI, because they may necessitate a change in treatment strategy that could lead to an improvement in prognosis due to early introduction of therapy, nonbrain lesions should also be given greater attention, given the increasing survival of patients with cancer and advances in MRI technology, such as contrast-enhanced-3D T1-weighted imaging.